Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Other Non-Current Assets (2016 - 2025)

IGC Pharma has reported Other Non-Current Assets over the past 15 years, most recently at $672000.0 for Q3 2025.

  • Quarterly Other Non-Current Assets fell 2.18% to $672000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $672000.0 through Sep 2025, down 2.18% year-over-year, with the annual reading at $681000.0 for FY2025, 1.02% down from the prior year.
  • Other Non-Current Assets was $672000.0 for Q3 2025 at IGC Pharma, down from $680000.0 in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $1.0 million in Q4 2022 and troughed at $18000.0 in Q2 2021.
  • The 5-year median for Other Non-Current Assets is $676000.0 (2025), against an average of $534888.9.
  • Year-over-year, Other Non-Current Assets soared 5022.22% in 2022 and then plummeted 97.37% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $612000.0 in 2021, then skyrocketed by 67.97% to $1.0 million in 2022, then plummeted by 97.37% to $27000.0 in 2023, then surged by 2422.22% to $681000.0 in 2024, then decreased by 1.32% to $672000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Other Non-Current Assets are $672000.0 (Q3 2025), $680000.0 (Q2 2025), and $681000.0 (Q1 2025).